BRPI0517647A - combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina - Google Patents

combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina

Info

Publication number
BRPI0517647A
BRPI0517647A BRPI0517647-6A BRPI0517647A BRPI0517647A BR PI0517647 A BRPI0517647 A BR PI0517647A BR PI0517647 A BRPI0517647 A BR PI0517647A BR PI0517647 A BRPI0517647 A BR PI0517647A
Authority
BR
Brazil
Prior art keywords
combinations
alpha
receptor agonists
nicotinically
acetylcholine receptor
Prior art date
Application number
BRPI0517647-6A
Other languages
English (en)
Inventor
Hans O Kalkman
Joachim Nozulak
Annick Vassout
Konstanze Hurth
Dominik Feuerbach
Conrad Gentsch
Graeme Bilbe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0517647A publication Critical patent/BRPI0517647A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMBINAçõES DE AGONISTAS DO RECEPTOR NICOTìNICO ALFA 7 DE ACETILCOLINA. A presente invenção refere-se a combinações que compreendem pelo menos um agonista do receptor nicotínico alfa 7 de acetilcolina e pelo menos um composto selecionado a partir do grupo que consiste em (a) antipsicóticos convencionais (b) antipsicóticos atípicos (c) intensificadores de memória e/ou atenção, cognição (d) e para uso destas combinações no tratamento de distúrbios psiquiátricos.
BRPI0517647-6A 2004-11-05 2005-11-03 combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina BRPI0517647A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424564A GB0424564D0 (en) 2004-11-05 2004-11-05 Organic compounds
PCT/EP2005/011787 WO2006048294A1 (en) 2004-11-05 2005-11-03 Combinations of nicotinic acetylcholine alpha 7 receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0517647A true BRPI0517647A (pt) 2008-10-14

Family

ID=33523294

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517647-6A BRPI0517647A (pt) 2004-11-05 2005-11-03 combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina

Country Status (12)

Country Link
US (2) US20080306081A1 (pt)
EP (3) EP2135609A1 (pt)
JP (3) JP2008518896A (pt)
KR (2) KR101302898B1 (pt)
CN (1) CN101039670A (pt)
AU (1) AU2005300691A1 (pt)
BR (1) BRPI0517647A (pt)
CA (1) CA2582436C (pt)
GB (1) GB0424564D0 (pt)
MX (1) MX2007005428A (pt)
RU (1) RU2007120690A (pt)
WO (1) WO2006048294A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008533142A (ja) * 2005-03-18 2008-08-21 アボット・ラボラトリーズ α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
EP2258357A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2009219050B2 (en) * 2008-02-29 2014-04-24 Biolab Sanus Farmaceutica Ltda. Pharmaceutical composition comprising racetam and carnitine and process for its preparation
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
CN103260619A (zh) * 2010-07-26 2013-08-21 英维沃医药有限公司 利用某些α-7烟酸受体激动剂与乙酰胆碱酯酶抑制剂的组合治疗认知障碍
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EA201391348A8 (ru) * 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
CA3199760A1 (en) * 2020-11-25 2022-06-02 Vanda Pharmaceuticals Inc. Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB261309A (en) 1926-07-23 1926-11-18 Oswald Pfeiffer Improvements in collapsible grids
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
MXPA04000779A (es) * 2001-08-24 2004-04-20 Pharmacia & Up John Company 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
MXPA04004464A (es) * 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
US7176198B2 (en) * 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
AU2003250322B2 (en) 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
WO2004039321A2 (en) * 2002-10-29 2004-05-13 Miicro, Inc. Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease
WO2004052461A1 (en) * 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
WO2010022556A1 (zh) 2008-08-27 2010-03-04 中兴通讯股份有限公司 一种下行信号的分扇区处理方法及基站
US10066977B2 (en) 2009-01-26 2018-09-04 Canon U.S. Life Sciences, Inc. Microfluidic flow monitoring

Also Published As

Publication number Publication date
EP2135609A1 (en) 2009-12-23
GB0424564D0 (en) 2004-12-08
US20080306081A1 (en) 2008-12-11
AU2005300691A1 (en) 2006-05-11
KR20070073881A (ko) 2007-07-10
JP2008518896A (ja) 2008-06-05
CA2582436C (en) 2016-10-04
RU2007120690A (ru) 2008-12-10
JP2014196328A (ja) 2014-10-16
WO2006048294A1 (en) 2006-05-11
MX2007005428A (es) 2007-05-18
EP2332537A1 (en) 2011-06-15
EP1809285A1 (en) 2007-07-25
CA2582436A1 (en) 2006-05-11
CN101039670A (zh) 2007-09-19
JP2012255039A (ja) 2012-12-27
KR101302898B1 (ko) 2013-09-06
US20100125063A1 (en) 2010-05-20
KR20130024974A (ko) 2013-03-08

Similar Documents

Publication Publication Date Title
BRPI0517647A (pt) combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
CL2012002521A1 (es) Composicion farmaceutica que comprende un inhibidor de dpp iv seleccionado de un grupo definido, un primer diluyente, un segundo diluyente: manitol, un segundo diluyente: almidon pregelatinizado, un aglutinante y un lubricante; util en el tratamiento de diabetes. (divisional de la sol. 1260-07).
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
CR9690A (es) 3-acilaminobenzanilidas insecticidas
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
CY1113734T1 (el) Χημικες ενωσεις
WO2007070359A3 (en) Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
NO20065417L (no) Muskarine acetylkolinreceptorantagonister
BRPI0620436B8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
ATE478069T1 (de) 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
ATE528302T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
GT200500246A (es) Combinacion de compuestos organicos
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]